+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors

Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors

Infection 41(6): 1195-1198

(PDF emailed within 0-6 h: $19.90)

Accession: 052164227

Download citation: RISBibTeXText

PMID: 24037723

DOI: 10.1007/s15010-013-0522-z

Related references

A retrospective study on the effects of colistin therapy in children with multidrug-resistant Gram-negative bacterial pathogens: impact of HIV status on outcome. Archives of Disease in Childhood 99(3): 262-266, 2014

Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clinical Microbiology and Infection 12(12): 1227-1230, 2006

Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study. Annals of Saudi Medicine 36(3): 216-222, 2016

Pharmacokinetics of colistin in critically ill patients with multidrug-resistant Gram-negative bacilli infection. European Journal of Clinical Pharmacology 69(7): 1429-1436, 2013

Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. Journal of Infection 56(3): 185-190, 2008

Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. International Journal of Antimicrobial Agents 35(3): 297-300, 2010

Spectrum and risk factors of multidrug-resistant gram-negative bacterium infection in liver transplant. 2011

Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. Journal of Clinical Microbiology 51(6): 1678-1684, 2013

Risk factors for nosocomial bloodstream infection caused by multidrug resistant gram-negative bacilli in pediatrics. Brazilian Journal of Infectious Diseases 11(2): 267-271, 2007

Clinical and microbiological efficacy and toxicity of colistin in patients infected with multidrug-resistant gram-negative pathogens. Journal of Infection and ChemoTherapy 19(1): 57-62, 2013

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrobial Agents and ChemoTherapy 49(8): 3136-3146, 2005

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. International Journal of Antimicrobial Agents 35(2): 194-199, 2010

Infection with multidrug-resistant gram-negative bacteria in a pediatric oncology intensive care unit: risk factors and outcomes. Jornal de Pediatria 91(5): 435-441, 2016

Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. Journal of Antimicrobial ChemoTherapy 66(3): 657-663, 2011

Clinical assessment of colistin in treating infections caused by multidrug-resistant gram-negative bacillus in patients with severe burn. Zhonghua Shao Shang Za Zhi 25(5): 372-376, 2010